SCHEMBL2482873

SCHEMBL2482873

COC(=O)c1ccc(N2CCCCC2C(=O)OC)c([N+](=O)[O-])c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.56
MAPT P10636 7/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
POLB P06746 2/20 0.51
ALDH1A1 P00352 6/20 0.50
GAA P10253 2/20 0.50
CYP1A2 P05177 3/20 0.49
CYP2D6 P10635 3/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2C19 P33261 3/20 0.49
CYP3A4 P08684 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
PKM P14618 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 1/20 0.48
OPRK1 P41145 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19984594 0.83 KMT2A (0.50) HPGDMAPTMEN1KMT2APOLB
SCHEMBL696233 0.83 MAPT (0.51) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL19732136 0.83 MAPT (0.53) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL8084718 0.82 SMN1; SMN2 (0.46) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL195322 0.82 ALDH1A1 (0.70) HPGDMAPTMEN1KMT2APOLB
SCHEMBL708077 0.81 OPRK1 (0.64) HPGDMAPTMEN1KMT2APOLB
SCHEMBL708078 0.81 OPRK1 (0.64) HPGDMAPTMEN1KMT2APOLB
SCHEMBL17813139 0.80 MAPT (0.48) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL29114204 0.80 MAPT (0.47) HPGDMAPTMEN1KMT2APOLB
SCHEMBL14334569 0.79 MAPT (0.59) HPGDMAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421763-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2019-09-24 US disclosed
US-20180086777-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. (US) 2018-03-29 US disclosed
US-9738659-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2017-08-22 US disclosed
US-9738659-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2017-08-22 US disclosed
US-9738659-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2017-08-22 US disclosed
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2015-08-06 US disclosed
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2015-08-06 US disclosed
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2015-08-06 US disclosed
US-9040508-B2 Compositions of protein receptor tyrosine kinase inhibitors VM PHARMA LLC (US) 2015-05-26 US disclosed
US-9040508-B2 Compositions of protein receptor tyrosine kinase inhibitors VM PHARMA LLC (US) 2015-05-26 US disclosed
US-8809530-B1 Compositions of protein receptor tyrosine kinase inhibitors VM PHARMA LLC (US) 2014-08-19 US disclosed
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. 2014-08-14 US disclosed
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. 2014-08-14 US disclosed
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. 2014-08-14 US disclosed
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 US disclosed
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 US disclosed
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 US disclosed
EP-2376495-A2 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM Pharma LLC (US) 2011-10-19 EP disclosed
WO-2010077680-A2 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM DISCOVERY INC. (US) 2010-07-08 WO disclosed
WO-2010077680-A2 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM DISCOVERY INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 HPGD 3363/4885MAPT 576/4885MEN1 4258/4885
US-10421763-B2 Compositions of protein receptor tyrosine kinase inhibitors NGFR, NGF, GRB2 HPGD 3363/4885MAPT 576/4885MEN1 4258/4885
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 HPGD 3363/4885MAPT 576/4885MEN1 4258/4885
US-20180086777-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 HPGD 3312/4885MAPT 536/4885MEN1 4121/4885
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 HPGD 3363/4885MAPT 576/4885MEN1 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.